STOCK TITAN

vTv Therapeutics Inc. Class A - VTVT STOCK NEWS

Welcome to our dedicated news page for vTv Therapeutics Class A (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on vTv Therapeutics Class A .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect vTv Therapeutics Class A 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of vTv Therapeutics Class A 's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
-
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.72%
Tags
none
-
vTv Therapeutics Inc. Class A

Nasdaq:VTVT

VTVT Rankings

VTVT Stock Data

68.02M
835.88k
54.68%
16.06%
1.33%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
HIGH POINT

About VTVT

vtv therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. we have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer.